A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results

被引：95

作者：

Wohl, David ^{[1
]}

Oka, Shinichi ^{[2
]}

Clumeck, Nathan ^{[3
]}

Clarke, Amanda ^{[4
]}

Brinson, Cynthia ^{[5
]}

Stephens, Jeffrey ^{[6
]}

Tashima, Karen ^{[7
]}

Arribas, Jose R. ^{[8
]}

Rashbaum, Bruce ^{[9
]}

Cheret, Antoine ^{[10
]}

Brunetta, Jason ^{[11
]}

Mussini, Cristina ^{[12
]}

Tebas, Pablo ^{[13
,14
]}

Sax, Paul E. ^{[15
,16
,17
]}

Cheng, Andrew ^{[18
]}

Zhong, Lijie ^{[18
]}

Callebaut, Christian ^{[18
]}

Das, Moupali ^{[18
]}

Fordyce, Marshall ^{[18
]}

机构：

[1] Univ N Carolina, Dept Med, CB 7030,Bioinformat Bldg,130 Mason Farm Rd, Chapel Hill, NC 27599 USA

[2] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan

[3] CHU St Pierre Univ Hosp Brussels, Dept Infect Dis, Brussels, Belgium

[4] Brighton & Sussex Univ Hosp NHS Trust, Elton John Ctr, Brighton, E Sussex, England

[5] Cent Texas Clin Res, Austin, TX USA

[6] Mercer Univ, Sch Med, Dept Internal Med, Macon, GA 31207 USA

[7] Brown Univ, Miriam Hosp, Alpert Med Sch, Providence, RI USA

[8] Hosp Univ La Paz, IdiPAZ, Internal Med Serv, Infect Dis Unit, Madrid, Spain

[9] Capital Ctr Travel & Trop Med, Washington, DC USA

[10] Ctr Hosp Tourcoing Descartes Univ, Necker Hosp, Le Kremlin Bicetre Hosp, AP HP,Infect Dis Unit,Internal Med Unit, Paris, France

[11] Univ Toronto, Dept Family & Community Med, Maple Leaf Res, Med, Toronto, ON M5S 1A1, Canada

[12] Univ Modena & Reggio Emilia, Clin Malattie Infett & Tropicali, Modena, Italy

[13] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA

[14] Univ Penn, Perelman Sch Med, Ctr AIDS Res, Philadelphia, PA 19104 USA

[15] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA

[16] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA

[17] Harvard Univ, Sch Med, Boston, MA USA

[18] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2016年 / 72卷 / 01期

关键词：

tenofovir alafenamide; integrase inhibitor; randomized controlled trial; HIV; bone mineral density; renal safety; ANTIRETROVIRAL-NAIVE; ABACAVIR-LAMIVUDINE; EFAVIRENZ; THERAPY; DENSITY; SAFETY;

D O I：

10.1097/QAI.0000000000000940

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In 2 double-blinded Phase 3 trials, 1733 antiretroviral-naive participants were randomized to tenofovir alafenamide (TAF), a tenofovir prodrug versus tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At 96 weeks, 86.6% in the TAF arm and 85.2% in the TDF arm had HIV-1 RNA <50 c/mL [difference 1.5%; (95% CI: -1.8% to 4.8%)]. With TAF, there are smaller declines in bone mineral density and more favorable changes in proteinuria, albuminuria, and tubular proteinuria, and no cases of proximal tubulopathy compared with 2 for TDF. These longer-term data support E/C/F/TAF as a safe, welltolerated, and durable regimen for initial HIV-1 treatment.

引用

页码：58 / 64

页数：7

共 50 条

[1] A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
Zolopa, Andrew
Sax, Paul E.
DeJesus, Edwin
Mills, Anthony
Cohen, Calvin
Wohl, David
Gallant, Joel E.
Liu, Hui C.
Plummer, Andrew
White, Kirsten L.
Cheng, Andrew K.
Rhee, Martin S.
Szwarcberg, Javier
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (01) : 96 - 100
[2] Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results
Arribas, Jose R.
Thompson, Melanie
Sax, Paul E.
Haas, Bernhard
McDonald, Cheryl
Wohl, David A.
DeJesus, Edwin
Clarke, Amanda E.
Guo, Susan
Wang, Hui
Callebaut, Christian
Plummer, Andrew
Cheng, Andrew
Das, Moupali
McCallister, Scott
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (02) : 211 - 218
[3] Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Sax, Paul E.
Wohl, David
Yin, Michael T.
Post, Frank
DeJesus, Edwin
Saag, Michael
Pozniak, Anton
Thompson, Melanie
Podzamczer, Daniel
Molina, Jean Michel
Oka, Shinichi
Koenig, Ellen
Trottier, Benoit
Andrade-Villanueva, Jaime
Crofoot, Gordon
Custodio, Joseph M.
Plummer, Andrew
Zhong, Lijie
Cao, Huyen
Martin, Hal
Callebaut, Christian
Cheng, Andrew K.
Fordyce, Marshall W.
McCallister, Scott
LANCET, 2015, 385 (9987) : 2606 - 2615
[4] Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
Cid-Silva, Purificacion
Fernandez-Bargiela, Noelia
Margusino-Framinan, Luis
Balboa-Barreiro, Vanesa
Mena-De-Cea, Alvaro
Lopez-Calvo, Soledad
Vazquez-Rodriguez, Pilar
Martin-Herranz, Isabel
Miguez-Rey, Enrique
Poveda, Eva
Castro-Iglesias, Angeles
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (04) : 479 - 490
[5] A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
Rockstroh, Juergen K.
DeJesus, Edwin
Henry, Keith
Molina, Jean-Michel
Gathe, Joseph
Ramanathan, Srinivasan
Wei, Xuelian
Plummer, Andrew
Abram, Michael
Cheng, Andrew K.
Fordyce, Marshall W.
Szwarcberg, Javier
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (05) : 483 - 486
[6] Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients
Huang, Yu-Shan
Cheng, Chien-Yu
Sun, Hsin-Yun
Cheng, Shu-Hsing
Lu, Po-Liang
Lee, Chen-Hsiang
Lee, Yuan-Ti
Tsai, Hung-Chin
Yang, Chia-Jui
Liu, Chun-Eng
Liou, Bo-Huang
Lin, Shih-Ping
Huang, Sung-Hsi
Ho, Mao-Wang
Tang, Hung-Jen
Hung, Chien-Ching
MICROBIOLOGY SPECTRUM, 2023, 11 (03):
[7] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment
Olin, Jacqueline L.
Spooner, Linda M.
Klibanov, Olga M.
ANNALS OF PHARMACOTHERAPY, 2012, 46 (12) : 1671 - 1677
[8] Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Margot, Nicolas
Cox, Stephanie
Das, Moupali
McCallister, Scott
Miller, Michael D.
Callebaut, Christian
ANTIVIRAL THERAPY, 2017, 22 (05) : 443 - 446
[9] Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
Cohen, Calvin
Elion, Richard
Ruane, Peter
Shamblaw, David
DeJesus, Edwin
Rashbaum, Bruce
Chuck, Steven L.
Yale, Kitty
Liu, Hui C.
Warren, David R.
Ramanathan, Srinivasan
Kearney, Brian P.
AIDS, 2011, 25 (06) : F7 - F12
[10] Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial
Post, Frank A.
Yazdanpanah, Yazdan
Schembri, Gabriel
Lazzarin, Adriano
Reynes, Jacques
Maggiolo, Franco
Yan, Mingjin
Abram, Michael E.
Tran-Muchowski, Cecilia
Cheng, Andrew
Rhee, Martin S.
HIV CLINICAL TRIALS, 2017, 18 (03): : 135 - 140

← 1 2 3 4 5 →